Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels.
More From BioPortfolio on "Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels"